Kidney Cancer Trial Results
- Sorafenib Increases the Risk of High Blood Pressure
(Posted: 04/02/2008) - Combined data from nine studies showed that patients receiving the standard amount of sorafenib (Nexavar®), an anticancer drug that interferes with a tumor's blood supply, run a significant risk of high blood pressure (hypertension), according to the February 2008 Lancet Oncology.
- Bevacizumab (Avastin®) Benefits Some Patients With Advanced Kidney Cancer
(Posted: 06/20/2007, Updated: 01/22/2008) - Addition of the targeted drug bevacizumab (Avastin®) to interferon alfa staved off disease progression for significantly longer than a placebo in patients with advanced kidney cancer, according to findings presented at the 2007 ASCO meeting in Chicago.